SCHEMBL5036770

SCHEMBL5036770

N#Cc1c(-c2ccco2)nc(N)nc1N1CCCCC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 6/20 0.58
ADORA2B P29275 3/20 0.58
ADORA1 P30542 3/20 0.58
ALDH1A1 P00352 8/20 0.56
HPGD P15428 8/20 0.56
KDM4E B2RXH2 7/20 0.56
GAA P10253 1/20 0.56
HIF1A Q16665 1/20 0.56
TDP1 Q9NUW8 1/20 0.56
HSD17B10 Q99714 5/20 0.55
MAPT P10636 5/20 0.55
CASP1 P29466 2/20 0.55
CASP7 P55210 2/20 0.55
ATM Q13315 2/20 0.55
LMNA P02545 2/20 0.55
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
ERAP1 Q9NZ08 1/20 0.54
PLAU P00749 1/20 0.47
RXFP1 Q9HBX9 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6446517 0.89 KDM4E (0.67) ADORA2AADORA2BADORA1ALDH1A1HPGD
SCHEMBL6448539 0.88 ADORA2A (0.56) ADORA2AADORA2BADORA1ALDH1A1HPGD
SCHEMBL6445134 0.87 ADORA2A (0.61) ADORA2AADORA2BADORA1ALDH1A1HPGD
SCHEMBL5131931 0.82 ADORA2A (0.55) ADORA2AADORA2BADORA1ALDH1A1HPGD
SCHEMBL6446501 0.81 HPGD (0.62) ADORA2AADORA2BADORA1ALDH1A1HPGD
SCHEMBL6442955 0.80 ADORA2A (0.64) ADORA2AADORA2BADORA1ALDH1A1HPGD
SCHEMBL6441202 0.77 ADORA2A (0.72) ADORA2AADORA2BADORA1ALDH1A1HPGD
SCHEMBL5041600 0.76 ADORA2A (0.70) ADORA2AADORA2BADORA1ALDH1A1HPGD
SCHEMBL6446329 0.76 ALDH1A1 (0.52) ADORA2AADORA2BADORA1ALDH1A1HPGD
SCHEMBL6445430 0.76 ADORA1 (0.50) ADORA2AADORA2BADORA1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4064671-B2 2008-03-19 JP claimed
EP-1261327-B1 ADENOSINE RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2005-04-27 EP claimed
JP-2003523380-A 2003-08-05 JP claimed
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US claimed
EP-1261327-A2 ADENOSINE RECEPTOR MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2002-12-04 EP claimed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US claimed
WO-2001062233-A2 ADENOSINE RECEPTOR MODULATORS F. HOFFMANN LA ROCHE AG (CH) 2001-08-30 WO claimed
EP-1261327-B1 ADENOSINE RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2005-04-27 EP disclosed
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
EP-1261327-A2 ADENOSINE RECEPTOR MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2002-12-04 EP disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed
WO-2001062233-A2 ADENOSINE RECEPTOR MODULATORS F. HOFFMANN LA ROCHE AG (CH) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 ADORA2A 1/4885ADORA2B 2/4885ADORA1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.